All In Biotech

Drug Trial Radar · NCT05080361

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer

Rechallenge of Rapidly Accelerated Fibrosarcoma B-type (BRAF) +/- Mitogen-activated Extracellular Signal-regulated Kinase (MEK) Inhibitors Following an Adverse Event in Patients With Cancer

Last checked: Nov 20, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

16,000

Planned (sponsor's estimate)

Start

Jan 1, 2011

Primary completion

Mar 1, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
University Hospital, CaenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 15, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes

Summary

As written by the sponsor on the registry.

Very little data are published on the safety of a rechallenge with a BRAF inhibitor or combination of BRAF and MEK inhibitor (BRAFi and MEKi) after an adverse event (AE). This study aimed at identifying the recurrence rate of the same AE after a BRAFi +/- MEKi rechallenge in patients with cancer and the factors associated to the recurrence.

Conditions

  • Cancer

Interventions

  • BRAF inhibitorDrug

    Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence rateTime frame: Up to the date of the individual case safety report notification in VigiBase(r), assessed up to 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.